Orgenesis Inc.

Come see Kristine Nishida speak at the ISCT, International Society for Cell & Gene Therapy's annual meeting. You won't want to miss her poster either (Addressing Challenges in Potency Assay Development for CAR-T Products in Decentralized Manufacturing: A Case Study from Orgenesis MD) Session Details below: Roundtable Title: Enabling Point-of-Care Manufacturing: The Need to Improve QC Assays   • Roundtable Date: Wednesday, May 29, 2024   • Roundtable Time: 10:45 AM - 11:45 AM PT

The Germfree and Orgenesis Inc. teams are in action, working to enable broader adoption of life-saving treatments and advance the field of cell and gene therapy! 💪 Get the details on how Germfree and Orgenesis intend to transform the production of cell and gene therapies to make these vital treatments more affordable and accessible to patients worldwide. ➡️ https://hubs.ly/Q02wlwrH0 #CellandGeneTherapy #DecentralizedManufacturing #CGT #PatientAccess

In case you missed it yesterday, learn more about our exciting #cellandgenetherapy #collaboration with Germfree below: Germfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global #Accessibility https://lnkd.in/eiW_Gb5u

Thank you again to Cambridge Healthtech Institute, Brian Caine and all of his wonderful colleagues for organizing this fantastic event. Our CEO Vered Caplan is always eager and excited to discuss the merits of decentralized manufacturing for #celltherapy #CHIBioprocessingSummitEurope

The close of 2023 is upon us, but we have one more opportunity to hear Sagi Nahum speak about leveraging analytics to enable #manufacturing #decentralization for #cellandgenetherapies. Don't miss him tomorrow at 4pm CET during the Informa #CellGene Therapy Manufacturing & Commercialization event in Dublin:

Today's the day! Our own Vered Caplan will be part of the ISPE Expert Xchange at 10:30am EST on Distributed & #Decentralized #Manufacturing for #cellandgenetherapies. Let's keep moving the conversation forward as an industry to change patient lives.

"In theory, PoC #manufacturing makes sense. But in practice, it raises important questions, such as how #biopharma companies and #hospitals will work together to ensure product quality, process control, and regulatory compliance at each PoC site." Loved the point of care #cellandgenetherapy manufacturing discussion from Kerim Ozbilge, Ed Sullivan, and Brian Gavin of the EY Parthenon group in Cell & Gene. Also, we have answers to all those questions! Reach out any time for a chat.

If you had not heard, #PointOfCare #cellandgenetherapy is kind of our thing! Great to be featured on the topic in BioPharm International with experts from University of Maryland Baltimore County, and Merck Group. The time to make better #patient care a reality is now!

It is an honor to work with pioneers and advocates in the #California #cellandgenetherapy #manufacturing space like University of California, Davis with support from the California Institute for Regenerative Medicine (CIRM). The time is now to make these medicines an accessible reality!

Is Anti-Aging Possible or Even Desirable? This is question that we always come back to at some point in #medicine, and one that our CEO, Vered Caplan will address with a #panel tomorrow at 10am Pacific during the COSM #Technology Summit in Seattle, WA hosted by Discovery Institute.